Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on macular edema secondary to branch retinal vein occlusion

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on macular edema secondary to branch retinal vein occlusion - Comparative study of Be and TA on BRVO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001546

Enrollment

Registered

2008-12-02

Start date

2009-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular edema secondary to branch retinal vein occlusion

Interventions

duration: 12 months quantity: bevacizumab 1.25 mg number: no addition injection 3 months after primary injection and addition injection if the visual acuity decrease or the central retinal thicknes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: visual acuity less than 0.5 central retinal thickness more than 300 micro meter

Exclusion criteria

Exclusion criteria: glaucoma ocular pressure more than 21 mmHg inflammation disease diabetic retinopathy history of steroid therapy

Design outcomes

Primary

Measure	Time frame
variation on a logarithm of the minimum angle of resolution and variation on a central retinal thickness 1 month, 3 months, 6 months, 9 months, and 12 months after intravitreal injection.	—

Secondary

Measure	Time frame
fluorescin angiography before and 1 month, 3 months, 6 months, 9 months, and 12 months after intravitreal injection.	—

Countries

Japan

Contacts

Public ContactOsamu Sawada

Shiga University of Medical Science department of Ophthalmology

l-eye@belle.shiga-med.ac.jp077-548-2276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026